Articles tagged with G Protein Coupled Receptors
Researchers at Monash University have combined computer modelling with pharmacology to gain new insights into how the body interacts with novel drug treatments. The study reveals alternative drug recognition sites on G protein-coupled receptors, which play a role in virtually every biological process and most diseases.
Scientists at Scripps Research Institute have determined the 3D structure of the human glucagon receptor, a key drug target for type 2 diabetes. The study's findings provide new information on how cells regulate glucose levels and may aid in the development of treatments for glucose-related disorders.
Scientists have discovered a protein that binds to two 'orphan receptors' found in the brain, GPR37 and GPR37L1. This binding has been linked to neuroprotection and glioprotection, suggesting potential therapeutic applications for neurological diseases such as Parkinson's and stroke.
Researchers solved the structure of the smoothened receptor, finding it has a similar shape to GPCRs despite low genetic similarity. This discovery provides insight into the role of SMO in cancer and embryonic development, potentially leading to new treatments for skin cancer and other diseases.
Researchers at Duke University Medical Center discovered a three-dimensional image of beta-arrestin1, a protein that regulates GPCRs, revealing a striking difference in its active and inactive states. This finding suggests the presence of a general molecular mechanism controlling the activation of beta-arrestin1.
Scientists from VIB and KU Leuven discovered a new target molecule to develop a treatment against Alzheimer's disease. β-arrestin 2 plays a role in regulating the γ-secretase complex function and development of the disease. This research opens a new avenue for treating the disease at an early stage.
Researchers have mapped the 3D structure of CXCR1, a protein that detects inflammatory signals and triggers immune responses. The study's findings will enable the development of more precise drug targets and potentially lead to effective cancer treatments.
Researchers have published a detailed description of neurotensin's interaction with its receptor, suggesting a novel binding mechanism that may activate G-protein coupled receptors. This knowledge could lead to the development of better drugs for conditions such as Parkinson's disease and schizophrenia.
A recent study on rhodopsin in Xenopus rod photoreceptor cells reveals that the geometry of micro-compartments formed by incisures affects its signaling. The researchers found that boundary geometry, rather than heterogeneity in diffusion or bound fraction, explains differences in rhodopsin distribution
Recent studies have made significant progress in understanding GPCRs, shedding light on their structure and function. The high-resolution structures of several GPCR receptors, including the A2A adenosine receptor, have been determined, providing valuable insights into how these proteins interact with ligands.
Researchers have identified a pair of proteins, RGS7 and RGS11, that play an essential role in vision, particularly in dim light environments. The study reveals that these proteins help regulate cells' response to light, enabling the transmission of visual information to the brain.
Researchers at UCSD School of Medicine identified G protein-coupled receptors as potential biomarkers and therapeutic targets for chronic lymphocytic leukemia. The expression of specific GPCRs, such as VIPR1, is linked to disease stage and prognosis.
Three international teams describe in unprecedented detail the workings of G protein-coupled receptors (GPCRs), a major molecular target for drugs. GPCRs are essential to human life, involved in almost every physiological function, and malfunctions have been linked to dozens of diseases.
Scripps Research scientists have identified a specific region of the β2-adrenergic receptor where changes in structure lead to altered signaling function. The study's findings could lead to the development of highly selective therapeutic drugs targeting this receptor.
Researchers have determined the complete three-dimensional atomic structure of an activated GPCR complexing with its G protein, shedding light on transmembrane signaling. The beta-2 adrenergic receptor's function was unknown despite being a key target for anti-asthma and blood pressure medications.
The Penn team successfully grafted olfactory receptors onto carbon nanotubes, enabling the conversion of chemical signals into electrical signals. This technology has potential applications in pharmaceutical research and could help develop new treatments for diseases by targeting specific GPCRs.
Researchers from Scripps Research Institute determine a new structure of the human A2A adenosine receptor, bound to a full agonist, revealing a super stabilizing agonist. This finding has important implications for drug design, particularly for treating diseases such as Parkinson's and COPD.
A team of researchers has discovered that arrestin molecules bind to two rhodopsin molecules in bright light, but one in low light, challenging the long-held assumption of a single binding interaction. This finding has implications for understanding other senses and physiological functions controlled by G-protein coupled receptors.
The research team used single-molecule imaging to study G protein-coupled receptors (GPCRs) and found that they can interconvert between monomers and dimers. This understanding is crucial for predicting GPCR numbers in cells and blocking signal amplification by these molecules.
Researchers at Scripps Research Institute have solved the structure of the dopamine D3 receptor, a crucial step in understanding brain disorders and developing new drugs. The breakthrough could lead to more effective treatments for conditions such as schizophrenia.
The Life Sciences Discovery Fund has awarded a $5 million grant to Omeros Corporation to discover and develop new drugs. The company's proprietary screening technology aims to identify compounds that interact with orphan GPCRs, potentially leading to treatments for cancer, obesity, and neurological disorders.
Researchers have determined the structure of CXCR4, a protein that guides blood-forming stem cells, and its interactions with chemokine ligands. The findings may lead to new drugs for hematopoietic stem cell transplantation and treating HIV infection.
The new fluorescent biosensor could aid in the development of drugs targeting GPCRs, a crucial class of proteins present in cells. The biosensor uses fluoromodules to monitor protein activity and provides a homogeneous assay that can screen large numbers of molecules to identify new drug leads.
Researchers at Case Western Reserve University have successfully imaged the open state of a K+ channel, allowing for better understanding of its effectiveness in treating cardiovascular diseases. The study has implications for improving pharmaceutical efficiency and enhancing the quality of cardiovascular-related drugs.
The Scripps Research Institute has been awarded a $1.3 million grant to develop a series of tests at its Florida campus to explore the potential of GPR119, a protein that regulates glucose balance and weight gain. The goal is to identify small molecule compounds that can be used therapeutically.
Gilad Barnea will use the funding to develop a method for selectively monitoring the activation of each of the five dopamine receptors in the brain without interference from others. This could lead to more targeted treatments for mental illnesses and diseases such as schizophrenia, bipolar disorder, and Parkinson's disease.
Scientists at Duke University Medical Center have identified the molecular pathways triggered by niacin, which could lead to a revival of niacin-based treatments for cholesterol. The discovery suggests that a 'biased ligand' could be developed to target the beneficial effects of niacin while minimizing its flushing side effect.
The study provides a detailed understanding of the human A2A adenosine receptor, shedding light on its structure and potential drug targets. The findings suggest that the receptor has varying binding pockets, yielding opportunities for receptor diversity and ligand selectivity.
Research reveals that statins cause skeletal muscle damage through the activity of the gene atrogin-1. Inhibiting this gene's function could help protect against the side effect. Separate studies also link low levels of protein SHGB to metabolic syndrome and show how excess sugar contributes to its development.
Researchers have determined the first known structure of a human G protein-coupled receptor (GPCR), specifically the beta2-adrenergic receptor. This breakthrough promises to speed the discovery of new and improved drugs, as well as broaden our understanding of human health and disease.
Researchers have determined the precise picture of cell target for drugs, giving them greater control over treatment. The high-resolution structure of a human G-protein-coupled receptor, such as beta 2-adrenergic receptor, can direct the future design of drugs that precisely bind to specific receptors.
Researchers found that a loose connection between hormone and GPCR allows for stronger signal activation, potentially leading to more effective drug therapies. The study used thyrotropin-releasing hormone (TRH) as a model and suggests that a similar approach could be applied to other hormone-GPCR reactions.
The IUPHAR database provides comprehensive information on GPCRs, including drugs that act on them, target locations in the body, and diseases they may be involved in. This knowledge is freely available to all scientists and drug discoverers worldwide, offering a powerful tool for future research.
Researchers have discovered a potential mechanism to eliminate the unwanted taste of artificial sweeteners by inhibiting the natural termination of taste-receptor signals. By targeting specific receptors and kinases, scientists hope to develop more effective and pleasant sugar substitutes.
Researchers develop soluble mimics of GPCRs to study their interactions with G-proteins, potentially leading to new drugs for various medical conditions. The technology could also be used to screen for drugs that block malfunctioning GPCRs.
A £1.96m grant has enabled the development of unique technology that quickly tests drugs against human GPCRs, which are responsible for many diseases. The 'SepteCell' system uses yeast cells to screen drugs and provides detailed information on their effectiveness.
The grant will develop new technologies to study G protein-coupled receptors and transcription factors, crucial for physiological responses. Researchers aim to create flat panels with multiple GPCRs to quickly assess drug candidates' effects.
Researchers identified a novel class of G proteins in yeast that could play a role in sensing unique signals important for health and disease. The discovery offers potential for developing new drugs targeting G protein-coupled receptors, which are involved in various diseases.
Researchers have mapped the first crystal structure of rhodopsin, a key protein in vision and embryonic development. This breakthrough could lead to significant advances in understanding GPCRs' role in various physiological processes, including taste, heart function, and drug addiction.